Factor H Polymorphism Diagnostics for AMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating age-related macular degeneration (AMD) and membranoproliferative glomerulonephritis type 2 (MPGNII) are limited by the inability to effectively identify and modulate the complement system's regulation, particularly regarding polymorphisms and haplotypes in the Factor H and CFHR5 genes.
Innovation Solution
Developing diagnostic and therapeutic methods that involve detecting polymorphisms and haplotypes in the Factor H and CFHR5 genes to determine susceptibility and treating individuals by modulating the levels or activity of Factor H and CFHR5 proteins, including administering specific polypeptides, nucleic acids, or antibodies to manage disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for AMD and MPGNII, then the diagnosis process is simple, but the accuracy and ability to identify genetic predispositions is limited
Solution Approach 1:
The diagnostic method is segmented into multiple stages: initial screening for complement system abnormalities, followed by specific genetic testing for Factor H and CFHR5 polymorphisms, and finally comprehensive haplotype analysis. This segmentation allows the complex diagnostic process to be broken down into manageable steps, improving accuracy without overwhelming the diagnostic workflow
Solution Approach 2:
The patent implements preliminary genetic screening to identify individuals with specific polymorphisms (such as Y402H in Factor H) before disease manifestation or progression. This preliminary identification of high-risk individuals enables early intervention and monitoring, significantly improving diagnostic accuracy for AMD and MPGNII
2Adaptability or versatility
If the complement system is not effectively modulated, then treatment approaches are limited, but the complexity of identifying and targeting specific complement regulators is high
Solution Approach 1:
The treatment approach targets specific local defects in the complement regulatory system rather than attempting global modulation. By identifying specific polymorphisms in Factor H (such as Y402H) and CFHR5 genes, the treatment can be tailored to address the precise molecular defect, providing adaptable therapy for different genetic variants while maintaining manageable complexity
Solution Approach 2:
The patent employs parameter changes in the form of targeted gene therapy or protein replacement therapy that specifically addresses the molecular parameters affected by the polymorphisms. For example, administering functional Factor H protein or using antisense oligonucleotides to correct mutant transcripts changes the biochemical parameters of the complement system locally, providing versatile treatment options without requiring complete system redesign
Data Source
AI summary
The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.